Overview
- General practitioners reported on Saturday that many practices received influenza vaccine shipments late or in smaller quantities than ordered, with age‑specific products for people 60 and over most affected.
- The Paul‑Ehrlich‑Institut confirmed it began batch testing later than usual this year but said it had released 20.2 million doses by early November and did not see a nationwide shortage.
- Manufacturers and the national pharmacy association attributed the problem to later production and later batch release, while Sanofi said its high‑dose vaccine Efluelda was delivered on schedule.
- Practices must order vaccine doses roughly six to nine months ahead, which forces long forecasts, limits rapid restocking and leaves clinics exposed to financial loss if demand is misjudged.
- The delivery gaps are already creating extra work for staff — calling pharmacies and postponing appointments — and risk slowing the campaign for high‑risk groups unless supply timing or ordering rules change.